Table 3

Crude MDS/AML rates by treatment category

Treatment category

% (cases/no. in category) (95% CI)


2 years of follow up (n = 5790)


All patients

.29 (17/5790) (.17, .47)


Surgery only

0 (0/420) (0)


Surgery/radiation

.25 (7/2764) (.10, .52)


Surgery/chemotherapy

.16 (1/639) (.00, .87)


Surgery/radiation/chemotherapy

.41 (9/1959) (.21, .87)


Anthracycline regimen

.25 (5/1968) (.08, .59)


Non-anthracycline regimen

.47 (3/633) (.10, 1.38)


5 years of follow up (n = 4179)


All patients

.41 (17/4179) (.24, .65)


Surgery only

0 (0/222) (0)


Surgery/radiation

.24 (5/2058) (.08, .57)


Surgery/chemotherapy

.22 (1/461) (.01, 1.20)


Surgery/radiation/chemotherapy

.42 (6/1440) (.15, .90)


Anthracycline regimen

.15 (2/1368) (.02, .53)


Non-anthracycline regimen

.56 (3/531) (.12, 1.64)


Kaplan et al. BMC Cancer 2011 11:260   doi:10.1186/1471-2407-11-260

Open Data